IgG Levels and Wear Off Reflect Administration and Outcome
5:51 MIN
- CIDP
- GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
Wear-Off in IVIG and What it Means in Clinical Practice
16:21 MIN
- CIDP
Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.
SELECT A CHAPTER TO VIEW
Introduction
Introduction to wear-off effects
Monitoring wear-off effects
Combating wear-off effects
Conclusion
Clinical Studies for the Treatment of CIDP with Immunoglobulin
9:35 MIN
- CIDP
- MMN
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
8:25 MIN
- CIDP
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
NOW PLAYING
5:51
IgG Levels and Wear Off Reflect Administration and Outcome
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
NOW PLAYING
16:21
Wear-Off in IVIG and What it Means in Clinical Practice
Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.
NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
NOW PLAYING
8:25
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
Our Experts on CIDP
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
- CIDP
- MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
- CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Slides & Posters about CIDP
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculo...
PDF | 2.3 MB
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
PDF | 2.2 MB
Incidence of GBS and CIDP Following Influenza Vaccination
PDF | 155 KB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
Back to Top